Treatment of inguinal lymph node metastases in rectal cancer

2019 ◽  
Vol 45 (2) ◽  
pp. e44
Author(s):  
J. Hagemans ◽  
J. Rothbarth ◽  
C. Verhoef ◽  
J. Burger
2021 ◽  
Vol 37 (6) ◽  
pp. 395-424
Author(s):  
Cristopher Varela ◽  
Nam Kyu Kim

Despite innovative advancements, distally located rectal cancer remains a critical disease of challenging management. The crucial location of the tumor predisposes it to a circumferential resection margin (CRM) that tends to involve the anal sphincter complex and surrounding organs, with a high incidence of delayed anastomotic complications and the risk of the pelvic sidewall or rarely inguinal lymph node metastases. In this regard, colorectal surgeons should be aware of other issues beyond total mesorectal excision (TME) performance. For decades, the concept of extralevator abdominoperineal resection to avoid compromised CRM has been introduced. However, the complexity of deep pelvic dissection with poor visualization in low-lying rectal cancer has led to transanal TME. In contrast, neoadjuvant chemoradiotherapy (NCRT) has allowed for the execution of more sphincter-saving procedures without oncologic compromise. Significant tumor regression after NCRT and complete pathologic response also permit applying the watch-and-wait protocol in some cases, now with more solid evidence. This review article will introduce the current surgical treatment options, their indication and technical details, and recent oncologic and functional outcomes. Lastly, the novel characteristics of distal rectal cancer, such as pelvic sidewall and inguinal lymph node metastases, will be discussed along with its tailored and individualized treatment approach.


Onkologie ◽  
2009 ◽  
Vol 32 (12) ◽  
pp. 732-738 ◽  
Author(s):  
Michael Braun ◽  
Eva Wardelmann ◽  
Manuel Debald ◽  
Gisela Walgenbach-Bruenagel ◽  
Tobias Höller ◽  
...  

2019 ◽  
Vol 43 (12) ◽  
pp. 3198-3206 ◽  
Author(s):  
Y. Atef ◽  
T. W. Koedam ◽  
S. E. van Oostendorp ◽  
H. J. Bonjer ◽  
A. R. Wijsmuller ◽  
...  

2004 ◽  
Vol 28 (2) ◽  
pp. 109-113 ◽  
Author(s):  
Judy A. C. King ◽  
Catherine M. Listinsky ◽  
J. Allan Tucker

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13575-13575 ◽  
Author(s):  
M. Hetnal ◽  
K. Malecki ◽  
S. Korzeniowski ◽  
T. Zemelka

13575 Background: The aim of this paper is an assessment of results of adjuvant chemoradiotherapy in patients with rectal cancer with respect to prognostic factors, causes of treatment failures and treatment tolerance. Methods: 178 pts with Dukes’ stage B or C rectal cancer received postoperative chemoradiotherapy between 1993 and 2002. Median age was 62; 110 patients were males, 68 were females. Median follow-up time was 45 months. Main endpoints of the analysis were locoregional recurrence-free survival (LRRFS), distant relapse free survival (DRFS), disease free survival (DFS) and overall survival (OS). Kaplan-Meier method was used to calculate survival rates. Univariate and multivariate analyses of prognostic factors were performed using log rank and Cox’s proportional hazard method. Results: The 5-year LRRFS was 73%, DRFS was 80%, DFS was 61% and OS was 65%. Lymph node involvement and method of resection (AR favoured) were the only independent prognostic factors for LRRFS. Lymph node involvement, in particular when four or more are involved, was independent prognostic factors for DFS. For DRFS are histological grade, lymph node involvement and extracapsular extension of the lymph node metastases. For OS, the independent prognostic factors were infiltration of the pararectal fatty tissue, lymph node involvement in particular when four or more are involved, total number of chemotherapy cycles (at least six favoured). The 5-year LRRFS was 73%, DRFS was 80%, DFS was 61% and OS was 65%. Radiation therapy was well tolerated in 45% of patients. Most common early reactions were diarrhoea, nausea/vomiting and leucopoenia. Conclusions: Involvement of lymph nodes and method of resection were the only independent prognostic factors for LRRFS. Prognostic factors for OS were infiltration of the pararectal fatty tissue, lymph node metastases, four or more involved lymph nodes, total number of chemotherapy cycles. No significant financial relationships to disclose.


2020 ◽  
Vol 203 ◽  
pp. e136
Author(s):  
Pooja Unadkat* ◽  
Aaron Fleishman ◽  
Aria Olumi ◽  
Andrew Wagner ◽  
Peter Chang ◽  
...  

1994 ◽  
Vol 37 (1) ◽  
pp. 52-57 ◽  
Author(s):  
T. J. Saclarides ◽  
A. K. Bhattacharyya ◽  
C. Britton-Kuzel ◽  
D. Szeluga ◽  
S. G. Economou

Sign in / Sign up

Export Citation Format

Share Document